LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Search

Zentalis Pharmaceuticals Inc

Fermé

3.59 -1.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.48

Max

3.65

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	-619K -38M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+95.53% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-34M 261M
Ouverture précédente	4.69
Clôture précédente	3.59

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 juin 2026, 23:36 UTC

Résultats

Correction to Oracle Reports Higher 4Q Profit Article

10 juin 2026, 23:19 UTC

Actions en Tendance

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 juin 2026, 23:09 UTC

Principaux Mouvements du Marché

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 juin 2026, 23:04 UTC

Résultats

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 juin 2026, 20:44 UTC

Principaux Mouvements du Marché

Caterpillar Raises Quarterly Dividend 8%

10 juin 2026, 23:49 UTC

Acquisitions, Fusions, Rachats

Elliott: Northern Star Should Take No Options Off The Table

10 juin 2026, 23:48 UTC

Acquisitions, Fusions, Rachats

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 juin 2026, 23:48 UTC

Acquisitions, Fusions, Rachats

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 juin 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 juin 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 juin 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 juin 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 juin 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 juin 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 juin 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 juin 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 juin 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 juin 2026, 21:57 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:52 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:35 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:22 UTC

Résultats

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 juin 2026, 20:50 UTC

Market Talk

Résultats

Tech, Media & Telecom Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 juin 2026, 20:39 UTC

Market Talk

Résultats

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 juin 2026, 20:34 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 20:33 UTC

Résultats

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 juin 2026, 20:33 UTC

Market Talk

Résultats

Global Equities Roundup: Market Talk

10 juin 2026, 20:33 UTC

Market Talk

Résultats

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

95.53% hausse

Prévisions sur 12 Mois

Moyen 7 USD 95.53%

Haut 10 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

4

Achat

3

Maintien

0

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Autres valeurs du secteur

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat